CancerGuide Diagnostics, Inc. Inks Multi-Year License and Research Collaboration Pact with Duke University

Published: Apr 06, 2010

DURHAM, N.C.--(BUSINESS WIRE)--CancerGuide Diagnostics™, Inc. (CancerGuide™) today announced that it has entered into a research collaboration and licensing agreement with Duke University to discover and develop tests to support individualized cancer treatment decisions. This relationship provides CancerGuide with exclusive commercial rights to a portfolio of well-published and rigorously-validated molecular signatures that predict response for targeted therapeutics as well as collaborative access to clinical research and new molecular discoveries from Duke, one of the nation’s premier cancer research institutions.

Back to news